Thymosin Alpha-1 Activates Immune Cells to Shrink HIV Viral Reservoirs
A new in vitro study shows Thymosin α1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
Summary
Researchers at Fudan University found that Thymosin α1 (Tα1), a peptide with broad immune-stimulating properties, can prompt dendritic cells to secrete the IL-15/IL-15RA complex, which in turn activates CD8+ T cells and NK cells to suppress HIV-1 reservoirs. In lab experiments using immune cells from HIV-positive patients on antiretroviral therapy, Tα1-treated dendritic cells significantly boosted cytokine production in CD8+ T cells, reduced HIV p24 protein levels in CD4+ T cells, and lowered integrated HIV DNA. These effects were most pronounced in patients with stronger immune recovery, suggesting Tα1 could be a candidate adjunct therapy for HIV functional cure strategies.
Detailed Summary
The persistence of HIV-1 viral reservoirs in people on antiretroviral therapy (ART) remains the central obstacle to a functional cure. Even with undetectable viral loads, latently infected CD4+ T cells harbor integrated HIV DNA that can rebound if treatment stops. Current 'shock and kill' strategies aim to reactivate these latent viruses and then clear infected cells using cytotoxic immune cells — but CD8+ T cell exhaustion in chronic HIV infection limits this approach. This study investigated whether Thymosin α1 (Tα1), a thymic peptide already used clinically in China for COVID-19 and hepatitis B, could reinvigorate this immune clearance pathway via the IL-15 signaling axis.
The research team differentiated THP-1 monocytic cells into mature monocyte-derived dendritic cells (MoDCs) using a cytokine cocktail (GM-CSF, IL-4, TNF-α, ionomycin), with or without Tα1 (100 µg/mL). Bulk RNA sequencing of these MoDCs revealed significant transcriptional changes, with Tα1 upregulating genes involved in immune activation and cytokine secretion. Critically, Tα1-stimulated MoDCs secreted significantly higher levels of the IL-15/IL-15RA complex (p < 0.001), which can trans-present IL-15 to neighboring T and NK cells via IL-2Rβ/γ receptors.
To test functional consequences, the team co-cultured Tα1-treated MoDCs with PBMCs from HIV-positive patients on suppressive ART using a transwell system, adding the latency-reversing agent vorinostat (SAHA, 1 µM) and IL-2 (10 ng/mL) to simulate reservoir reactivation. In CD8+ T cells, Tα1-conditioned MoDC supernatant significantly increased intracellular secretion of CCL3, CCL5, IFN-γ, and TNF-α (p < 0.05). These functional changes translated into measurable reservoir suppression: intracellular HIV p24 levels in CD4+ T cells were significantly reduced (p = 0.002), and integrated HIV DNA levels fell significantly (p = 0.012). NK cell secretion of IFN-γ, TNF-α, and granzyme B also increased following co-culture.
A particularly notable finding involved virtual memory CD8+ T cells (T_VM) — a subset previously shown to help control chronic viral infections. The proportion of T_VM cells increased significantly after Tα1-conditioned co-culture, and their expansion was inversely correlated with reservoir size and reactivation capacity. T_VM cells are known to depend on IL-15 presented by dendritic cells for their homeostatic proliferation, providing a mechanistic link between Tα1, IL-15 secretion, and reservoir control.
Importantly, these effects were observed only in PBMCs from immunological responders (IR; CD4+ T cell count > 350 cells/µL), not in immunological nonresponders (INR; CD4+ < 350 cells/µL). This is a critical caveat: patients with the most severe immune dysfunction — who arguably need reservoir reduction most — did not benefit in this model. The authors suggest this may reflect a threshold of immune competence required for Tα1's mechanism to operate. The study is limited by its in vitro design using a cell line-derived DC model rather than primary patient DCs, and the small, select patient cohort. Clinical trials will be needed to confirm these findings.
Key Findings
- Tα1 stimulation of THP-1-derived MoDCs significantly increased IL-15/IL-15RA complex secretion (p < 0.001) compared to untreated controls
- Intracellular HIV p24 levels in CD4+ T cells were significantly reduced in Tα1-conditioned co-cultures (p = 0.002)
- Integrated HIV DNA levels fell significantly following Tα1-conditioned MoDC co-culture with PBMCs (p = 0.012)
- CD8+ T cell intracellular CCL3, CCL5, IFN-γ, and TNF-α secretion increased significantly after Tα1-conditioned co-culture (p < 0.05)
- NK cell secretion of IFN-γ, TNF-α, and granzyme B increased following co-culture with Tα1-treated MoDCs
- Virtual memory CD8+ T cell (T_VM) proportions increased and were inversely correlated with reservoir size and reactivation
- Beneficial effects were restricted to immunological responders (CD4+ > 350 cells/µL); immunological nonresponders showed no significant benefit
Methodology
THP-1 monocytic cells were differentiated into mature MoDCs using GM-CSF, IL-4, TNF-α, and ionomycin, with or without 100 µg/mL Tα1 for 4–6 days. Bulk RNA sequencing compared transcriptional profiles of Tα1-treated vs. untreated MoDCs. MoDCs were then co-cultured with PBMCs from ART-suppressed HIV-positive patients (HIV RNA < 50 copies/mL, ART > 1 year) in a transwell system with vorinostat (1 µM) and IL-2 (10 ng/mL) for 48 hours. Outcomes included flow cytometry for p24, CD8+ T cell cytokines, NK cell function, T_VM proportions, and integrated HIV DNA by PCR; statistical significance was assessed with p-values reported for each endpoint.
Study Limitations
This study is entirely in vitro, using a THP-1 cell line to model dendritic cells rather than primary patient-derived DCs, which may not fully recapitulate in vivo biology. The patient cohort was small and drawn from a single center in Shanghai, limiting generalizability. The authors note that immunological nonresponders — the most clinically challenging group — did not show benefit, and no conflicts of interest were declared, though Tα1 was gifted by SciClone Pharmaceuticals.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.